A Multi-centre Randomised Adaptive Platform Clinical Trial to Assess Clinical, Virological and Immunological Outcomes in Patients With SARS-CoV-2 Infection (COVID-19)

Tong et al., NCT04483960, ASCOT, NCT04483960, Dec 2025
Estimated 2,200 patient paxlovid late treatment RCT with results expected soon (estimated completion over 1 month ago).
Important missing comments or errors? Let us know.
Study covers remdesivir and paxlovid.
Tong et al., 31 Dec 2025, Randomized Controlled Trial, Australia, trial NCT04483960 (history) (ASCOT).
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0